EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas

Virchows Archiv

Volumn 461, Issue 3, 2012, Pages 271-282

  Suzuki, Shioto ^a,b   Dobashi, Yoh ^c   Minato, Hiroshi ^d   Tajiri, Ryosuke ^a   Yoshizaki, Tomokazu ^a   Ooi, Akishi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Iwata City Hospital   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Akt; EGFR; HER2; mTOR; Salivary gland carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN KINASE B;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CHROMOSOME 7; CLINICAL ARTICLE; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PEPTIDE MAPPING; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MUCOEPIDERMOID; DNA, NEOPLASM; FEMALE; GENE DUPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84867397439     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1282-3     Document Type: Article

References (35)

1. Barnes L, Eveson J, Reichart P, Sidransky D (eds) (2005) World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC, Lyon. pp 209-253
2. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3:237-252
3. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460 (Pubitemid 23100476)
4. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Overexpression of EGFR and absence of CKIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53:567-577
5. Williams MD, Roberts D, Blumenschein GR Jr, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK (2007) Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31:1645-1652 (Pubitemid 350287562)
6. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, Bossi P, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L (2009) Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 45:986-990
7. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266-2274
8. Sorensen KB, Godballe C, De Stricker K, Krogdahl A (2006) Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 35:286-291
9. Vered M, Braunstein E, Buchner A (2002) Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24:632-636 (Pubitemid 34734357)
10. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG et al (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675-5682 (Pubitemid 24346266)
11. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M (2004) HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10:944-946 (Pubitemid 38198894)
12. Bourhis J, Lefebvre JL, Vermorken JB (2010) Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options? Eur J Cancer 46:1979-1989
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
14. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26:3351-3357
15. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, Peralta S, Maacke H, Foernzler D, Parera M, Mocks J, Saura C, Gatzemeier U, Baselga J (2008) A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14:3867-3874
16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
17. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
18. Vidal L, Tsao MS, Pond GR, Cohen EE, Cohen RB, Chen EX, Agulnik M, Hotte S, Winquist E, Laurie S, Hayes DN, Ho J, Dancey J, Siu LL (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006-1012
19. Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A (2011) Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum Pathol 42:214-226
20. Suzuki S, Igarashi S, Hanawa M, Matsubara H, Ooi A, Dobashi Y (2006) Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol 19:986-998
21. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon y Cajal S (2007) 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67:7551-7555 (Pubitemid 47281345)
22. De Lima Mde D, Marques YM, Alves Sde M Jr, Freitas VM, Soares FA, De Araujo VC, Pinto Ddos S Jr, Mantesso A (2009) MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol 33:142-146
23. Edge SB, Byrd D, Compton CC, Fritz AG, Greene FL et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer-Verlag, New York
24. Ooi A, Zen Y, Ninomiya I, Tajiri R, Suzuki S, Kobayashi H, Imoto I, Dobashi Y (2010) Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. Pathol Int 60:466-471
25. Varella-Garcia M (2006) Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1:19
26. Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, Jasani B, Miller K, Pinder SE (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61:818-824 (Pubitemid 351969725)
27. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL (2001) HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14:1079-1086 (Pubitemid 33063199)
28. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174 (Pubitemid 8054849)
29. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim HD, Grantcharova V, Lauffenburger DA, White FM (2006) Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2:54
30. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257-2267 (Pubitemid 46801555)
31. Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K (2010) First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 46:920-925
32. Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, Kosmehl H (2009) Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 100:623-625
33. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286 (Pubitemid 40590264)
34. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S (2011) Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4:476-495
35. Chan SK, Hill ME, Gullick WJ (2006) The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 11:3-11 (Pubitemid 44309185)